MYCAPSSA
Total Payments
$2.3M
Transactions
5,802
Doctors
2,281
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $193,864 | 1,219 | 726 |
| 2023 | $502,454 | 1,962 | 1,134 |
| 2022 | $779,204 | 2,028 | 1,077 |
| 2021 | $833,298 | 593 | 242 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.3M | 494 | 58.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $360,600 | 151 | 15.6% |
| Consulting Fee | $291,997 | 106 | 12.6% |
| Food and Beverage | $131,111 | 4,703 | 5.7% |
| Travel and Lodging | $105,844 | 263 | 4.6% |
| Honoraria | $59,940 | 15 | 2.6% |
| Space rental or facility fees (teaching hospital only) | $10,750 | 9 | 0.5% |
| Education | $1,007 | 61 | 0.0% |
Payments by Type
Research
$1.3M
494 transactions
General
$961,249
5,308 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| MACRO Registry | Amryt Pharma Holdings Ltd | $500,617 | 2 |
| MACRO Registry | Chiasma, Inc. | $465,084 | 1 |
| OOC-AMC-302 | Amryt Pharma Holdings Ltd | $147,447 | 10 |
| The variation of IGF-1 levels during administration of long-acting somatostatin receptor ligands (SRLs): association with time since injection and symptoms of acromegaly | Amryt Pharma Holdings Ltd | $133,707 | 0 |
| A RANDOMIZED, OPEN-LABEL, CROSSOVER STUDY TO ESTIMATE THE RELATIVE BIOAVAILABILITY OF MYCAPSSA TO SUBCUTANEOUSLY ADMINISTERED SANDOSTATIN AND TO ASSESS THE DOSE PROPORTIONALITY OF MYCAPSSA | Chiasma, Inc. | $29,933 | 4 |
| OOC-AMC-302 | Chiasma, Inc. | $22,623 | 3 |
| OOC-AMC-303 | Chiasma, Inc. | $21,685 | 5 |
| OOC-AMC-303 | Amryt Pharma Holdings Ltd | $16,419 | 5 |
| A RANDOMIZED, OPEN-LABEL, CROSSOVER STUDY TO EVALUATE THE PHARMACOKINETICS OF THREE ESCALATING DOSES OF MYCAPSSA | Amryt Pharma Holdings Ltd | $10,058 | 4 |
Top Doctors Receiving Payments for MYCAPSSA — Page 91
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| , M.D | Internal Medicine | Bridgewater, NJ | $12.79 | 1 |
| , M.D | Endocrinology, Diabetes & Metabolism | Dearborn, MI | $12.77 | 1 |
| , M.D | Endocrinology, Diabetes & Metabolism | Ripley, MS | $12.77 | 1 |
| , MD | Emergency Medicine | Ripley, MS | $12.76 | 1 |
| , MD | Internal Medicine | Sandusky, OH | $12.72 | 1 |
| , MD | Endocrinology, Diabetes & Metabolism | Cincinnati, OH | $12.70 | 1 |
| , APRN FNP-C | Family | Amelia, OH | $12.69 | 1 |
| , M.D | Endocrinology, Diabetes & Metabolism | Ho Ho Kus, NJ | $12.62 | 1 |
| , MD | Family Medicine | Mount Clemens, MI | $12.57 | 1 |
| , MD | Endocrinology, Diabetes & Metabolism | Saint Louis, MO | $12.56 | 1 |
| , M.D | Endocrinology, Diabetes & Metabolism | Saint Louis, MO | $12.56 | 1 |
| , M.D | Internal Medicine | Johnstown, PA | $12.56 | 1 |
| , MD | Endocrinology, Diabetes & Metabolism | Saint Louis, MO | $12.56 | 1 |
| , MD | Internal Medicine | St Louis, MO | $12.56 | 1 |
| , M.D | Internal Medicine | Chesterfield, MO | $12.55 | 1 |
| , M.D | Endocrinology, Diabetes & Metabolism | Port Saint Lucie, FL | $12.51 | 1 |
| , MD | Internal Medicine | Johnson City, TN | $12.50 | 1 |
| , M.D | Endocrinology, Diabetes & Metabolism | Irvine, CA | $12.43 | 1 |
| , NP | Family | Oak Brook, IL | $12.40 | 1 |
| , FNP | Family | Chicago, IL | $12.40 | 1 |
| , M.D | Endocrinology, Diabetes & Metabolism | Sugar Land, TX | $12.28 | 1 |
| , MD | Specialist | Florham Park, NJ | $12.01 | 1 |
| , PA-C | Endocrinology, Diabetes & Metabolism | Portland, OR | $11.94 | 1 |
| , MD | Nephrology | Lufkin, TX | $11.91 | 1 |
| , PA-C | Medical | Lufkin, TX | $11.91 | 1 |
Ad
Manufacturing Companies
- Amryt Pharma Holdings Ltd $1.4M
- Chiasma, Inc. $740,383
- Chiesi USA, Inc. $193,864
Product Information
- Type Drug
- Total Payments $2.3M
- Total Doctors 2,281
- Transactions 5,802
About MYCAPSSA
MYCAPSSA is a drug associated with $2.3M in payments to 2,281 healthcare providers, recorded across 5,802 transactions in the CMS Open Payments database. The primary manufacturer is Amryt Pharma Holdings Ltd.
Payment data is available from 2021 to 2024. In 2024, $193,864 was paid across 1,219 transactions to 726 doctors.
The most common payment nature for MYCAPSSA is "Unspecified" ($1.3M, 58.4% of total).
MYCAPSSA is associated with 9 research studies, including "MACRO Registry" ($500,617).